BA/F3 |
Antitumor assay |
75 mg/kg |
19 days |
Antitumor activity against mouse BA/F3 cells expressing wild type Bcr-Abl xenografted in CB17 SCID mouse assessed as median survival time at 75 mg/kg, po administered on day 3 once daily for 19 days relative to control |
19572547 |
BA/F3 |
Antitumor assay |
75 mg/kg |
19 days |
Antitumor activity against mouse BA/F3 cells expressing wild type Bcr-Abl xenografted in CB17 SCID mouse assessed as increase in mouse survival at 75 mg/kg, po administered on day 3 once daily for 19 days relative to control |
19572547 |
vascular smooth muscle cells |
Antiangiogenic assay |
0.15 uM |
72 hrs |
Antiangiogenic activity in HUVEC co-cultured with vascular smooth muscle cells assessed as inhibition of cell growth at 0.15 uM after 72 hrs |
22853993 |
vascular smooth muscle cells |
Antiangiogenic assay |
10 to 15 uM |
72 hrs |
Antiangiogenic activity in HUVEC co-cultured with vascular smooth muscle cells assessed as inhibition of network formation at 10 to 15 uM after 72 hrs |
22853993 |
HEK293 |
Function assay |
0.1 to 1 uM |
16 hrs |
Inhibition of collagen I-induced DDR2 (unknown origin) phosphorylation expressed in HEK293 cells at 0.1 to 1 uM after 16 hrs by Western blotting |
26191369 |
HEK293 |
Function assay |
0.1 to 1 uM |
16 hrs |
Inhibition of collagen I-induced DDR2 I638F mutant (unknown origin) phosphorylation expressed in HEK293 cells at 0.1 to 1 uM after 16 hrs by Western blotting |
26191369 |
KU812 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against human KU812 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay, GI50 = 0.001 μM. |
26789553 |
BA/F3 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M244V mutant after 72 hrs by CCK-8 assay, IC50 = 0.00154 μM. |
23088644 |
K562 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against human K562 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay, GI50 = 0.002 μM. |
26789553 |
BA/F3 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL M351T mutant assessed as growth inhibition after 72 hrs by CCK-8 assay, IC50 = 0.003 μM. |
23301703 |
Ba/F3 |
Function assay |
|
48 hrs |
Inhibition of wild type BCR-ABL1 (unknown origin) expressed in mouse Ba/F3 cells assessed as inhibition of cell proliferation after 48 hrs by BriteLight luciferase assay, GI50 = 0.00352 μM. |
30137981 |
Ba/F3 |
Function assay |
|
48 hrs |
Inhibition of BCR-ABL1 G250H mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as inhibition of BCR-ABL1-mediated cell proliferation after 48 hrs by BriteLight luciferase assay, GI50 = 0.00371 μM. |
30137981 |
K562 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by MTT assay, IC50 = 0.0039 μM. |
26814890 |
BA/F3 |
Function assay |
|
72 hrs |
Inhibition of BCR/ABL p210 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay, GI50 = 0.004 μM. |
26789553 |
Ba/F3 |
Function assay |
|
48 hrs |
Inhibition of BCR-ABL1 E355G mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as inhibition of BCR-ABL1-mediated cell proliferation after 48 hrs by BriteLight luciferase assay, GI50 = 0.00482 μM. |
30137981 |
BA/F3 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396P mutant after 72 hrs by CCK-8 assay, IC50 = 0.00634 μM. |
23088644 |
BA/F3 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E355G mutant after 72 hrs by CCK-8 assay, IC50 = 0.00838 μM. |
23088644 |
Ba/F3 |
Function assay |
|
48 hrs |
Inhibition of BCR-ABL1 E459K mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as inhibition of BCR-ABL1-mediated cell proliferation after 48 hrs by BriteLight luciferase assay, GI50 = 0.00921 μM. |
30137981 |
BA/F3 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F486S mutant assessed as growth inhibition after 72 hrs by CCK-8 assay, IC50 = 0.0095 μM. |
23301703 |
BA/F3 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M351T mutant after 72 hrs by CCK-8 assay, IC50 = 0.0103 μM. |
23088644 |
insect cells |
Function assay |
|
30 mins |
Inhibition of human recombinant ABL1 M351T mutant expressed in insect cells after 30 mins by FRET assay, IC50 = 0.0128 μM. |
23301703 |
K562 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay, IC50 = 0.015 μM. |
23521020 |
insect cells |
Function assay |
|
30 mins |
Inhibition of human recombinant ABL1 H396P mutant expressed in insect cells after 30 mins by FRET assay, IC50 = 0.0158 μM. |
23301703 |
MEG01 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against human MEG01 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay, GI50 = 0.016 μM. |
26789553 |
BA/F3 |
Function assay |
|
72 hrs |
Inhibition of BCR/ABL p210-M351T mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay, GI50 = 0.017 μM. |
26789553 |
Ba/F3 |
Function assay |
|
48 hrs |
Inhibition of BCR-ABL1 Q252H mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as inhibition of BCR-ABL1-mediated cell proliferation after 48 hrs by BriteLight luciferase assay, GI50 = 0.0189 μM. |
30137981 |
BA/F3 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F486S mutant after 72 hrs by CCK-8 assay, IC50 = 0.021 μM. |
23088644 |
BA/F3 |
Function assay |
|
72 hrs |
Inhibition of BCR/ABL p210-E255K mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay, GI50 = 0.021 μM. |
26789553 |
BA/F3 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against mouse BA/F3 cells expressing wild type BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay, IC50 = 0.022 μM. |
23301703 |
K562 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against human K562 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay, IC50 = 0.022 μM. |
26195136 |
BA/F3 |
Function assay |
|
72 hrs |
Inhibition of BCR/ABL p210-Q252H mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay, GI50 = 0.023 μM. |
26789553 |
insect cells |
Function assay |
|
30 mins |
Inhibition of human recombinant ABL1 Q252H mutant expressed in insect cells after 30 mins by FRET assay, IC50 = 0.0242 μM. |
23301703 |
BA/F3 |
Function assay |
|
72 hrs |
Inhibition of BCR/ABL p210-H369P mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay, GI50 = 0.025 μM. |
26789553 |
insect cells |
Function assay |
|
30 mins |
Inhibition of human recombinant ABL1 E255K mutant expressed in insect cells after 30 mins by FRET assay, IC50 = 0.0278 μM. |
23301703 |
K562 |
Function assay |
|
30 mins |
Inhibition of kinobead binding to ABL in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method, IC50 = 0.028 μM. |
28280261 |
Ba/F3 |
Function assay |
|
48 hrs |
Inhibition of BCR-ABL1 F359V mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as inhibition of BCR-ABL1-mediated cell proliferation after 48 hrs by BriteLight luciferase assay, GI50 = 0.0296 μM. |
30137981 |
insect cells |
Function assay |
|
30 mins |
Inhibition of human recombinant ABL1 Y253F mutant expressed in insect cells after 30 mins by FRET assay, IC50 = 0.0299 μM. |
23301703 |
Ba/F3 |
Function assay |
|
48 hrs |
Inhibition of BCR-ABL1 E255K mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as inhibition of BCR-ABL1-mediated cell proliferation after 48 hrs by BriteLight luciferase assay, GI50 = 0.0369 μM. |
30137981 |
BA/F3 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl G250E mutant after 72 hrs by CCK-8 assay, IC50 = 0.0386 μM. |
23088644 |
insect cells |
Function assay |
|
30 mins |
Inhibition of human recombinant wild type ABL1 expressed in insect cells after 30 mins by FRET assay, IC50 = 0.0435 μM. |
23301703 |
BA/F3 |
Function assay |
|
72 hrs |
Inhibition of BCR/ABL p210-F317I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay, GI50 = 0.0546 μM. |
26789553 |
BA/F3 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253F mutant after 72 hrs by CCK-8 assay, IC50 = 0.0607 μM. |
23088644 |
Ba/F3 |
Function assay |
|
48 hrs |
Inhibition of BCR-ABL1 E255V mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as inhibition of BCR-ABL1-mediated cell proliferation after 48 hrs by BriteLight luciferase assay, GI50 = 0.0616 μM. |
30137981 |
BA/F3 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against mouse BA/F3 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay, IC50 = 0.0652 μM. |
23088644 |
BA/F3 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396R mutant after 72 hrs by CCK-8 assay, IC50 = 0.0872 μM. |
23088644 |
K562 |
Function assay |
|
30 mins |
Inhibition of kinobead binding to DDR1 in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method, IC50 = 0.1 μM. |
28280261 |
BA/F3 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E359V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay, IC50 = 0.12 μM. |
23301703 |
BA/F3 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Q252H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay, IC50 = 0.12 μM. |
23301703 |
BA/F3 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E355G mutant assessed as growth inhibition after 72 hrs by CCK-8 assay, IC50 = 0.13 μM. |
23301703 |
Ba/F3 |
Function assay |
|
48 hrs |
Inhibition of BCR-ABL1 Y253H mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as inhibition of BCR-ABL1-mediated cell proliferation after 48 hrs by BriteLight luciferase assay, GI50 = 0.132 μM. |
30137981 |
BA/F3 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Q252H mutant after 72 hrs by CCK-8 assay, IC50 = 0.15 μM. |
23088644 |
BA/F3 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL G250E mutant assessed as growth inhibition after 72 hrs by CCK-8 assay, IC50 = 0.15 μM. |
23301703 |
BA/F3 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F359V mutant after 72 hrs by CCK-8 assay, IC50 = 0.159 μM. |
23088644 |
BA/F3 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317L mutant assessed as growth inhibition after 72 hrs by CCK-8 assay, IC50 = 0.16 μM. |
23301703 |
BA/F3 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255K mutant assessed as growth inhibition after 72 hrs by CCK-8 assay, IC50 = 0.17 μM. |
23301703 |
BA/F3 |
Function assay |
|
72 hrs |
Inhibition of BCR/ABL p210-F317L mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay, GI50 = 0.202 μM. |
26789553 |
insect cells |
Function assay |
|
30 mins |
Inhibition of human recombinant ABL1 G250E mutant expressed in insect cells after 30 mins by FRET assay, IC50 = 0.2153 μM. |
23301703 |
BA/F3 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255K mutant after 72 hrs by CCK-8 assay, IC50 = 0.292 μM. |
23088644 |
BA/F3 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253H mutant after 72 hrs by CCK-8 assay, IC50 = 0.314 μM. |
23088644 |
BA/F3 |
Function assay |
|
72 hrs |
Inhibition of TEL-SRC (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay, GI50 = 0.47 μM. |
26789553 |
BA/F3 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255V mutant after 72 hrs by CCK-8 assay, IC50 = 0.473 μM. |
23088644 |
insect cells |
Function assay |
|
30 mins |
Inhibition of human recombinant ABL1 T315I mutant expressed in insect cells after 30 mins by FRET assay, IC50 = 0.7024 μM. |
23301703 |
BA/F3 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay, IC50 = 0.775 μM. |
23088644 |
BA/F3 |
Function assay |
|
72 hrs |
Inhibition of TEL-LCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay, GI50 = 0.87 μM. |
26789553 |
BA/F3 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay, IC50 = 1 μM. |
23301703 |
BA/F3 |
Function assay |
|
72 hrs |
Inhibition of BCR/ABL p210-Y253F mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay, GI50 = 1.093 μM. |
26789553 |
BA/F3 |
Function assay |
|
72 hrs |
Inhibition of TEL-DDR1 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay, GI50 = 1.1 μM. |
26789553 |
BA/F3 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay, IC50 = 1.2 μM. |
23301703 |
BA/F3 |
Function assay |
|
72 hrs |
Inhibition of TEL-BLK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay, GI50 = 1.3 μM. |
26789553 |
BA/F3 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253F mutant assessed as growth inhibition after 72 hrs by CCK-8 assay, IC50 = 1.4 μM. |
23301703 |
BA/F3 |
Function assay |
|
72 hrs |
Inhibition of TEL-DDR2 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay, GI50 = 1.4 μM. |
26789553 |
NCI-H2286 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against human NCI-H2286 cells expressing DDR2 mutant after 72 hrs by alamar blue assay, IC50 = 1.8 μM. |
26191369 |
K562 |
Function assay |
|
30 mins |
Inhibition of kinobead binding to NQO2 in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method, IC50 = 1.8 μM. |
28280261 |
BA/F3 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against mouse BA/F3 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay, GI50 = 2.1 μM. |
26789553 |
Ba/F3 |
Function assay |
|
48 hrs |
Inhibition of BCR-ABL1 T315I mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as inhibition of cell proliferation after 48 hrs by BriteLight luciferase assay, GI50 = 2.262 μM. |
30137981 |
HCT116 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay, IC50 = 2.39 μM. |
23521020 |
K562 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against apoptosis-resistant, Philadelphia chromosome-positive human K562 cells after 72 hrs by PrestoBlue colorimetric assay, IC50 = 2.4 μM. |
24835982 |
MDA-MB-435S |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against human MDA-MB-435S cells after 72 hrs by MTT assay, IC50 = 2.66 μM. |
23521020 |
BA/F3 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL T315I mutant after 72 hrs by MTT assay, IC50 = 2.7 μM. |
26814890 |
BA/F3 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay, IC50 = 2.9 μM. |
23301703 |
BA/F3 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL L248V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay, IC50 = 3 μM. |
23301703 |
NCI-H23 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against human NCI-H23 cells after 72 hrs by MTT assay, IC50 = 3.05 μM. |
23521020 |
HEL |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against human HEL cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay, GI50 = 3.9 μM. |
26789553 |
BA/F3 |
Function assay |
|
72 hrs |
Inhibition of TEL-HCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay, GI50 = 4.1 μM. |
26789553 |
CHL |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against human CHL cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay, GI50 = 4.2 μM. |
26789553 |
T47D |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against human T47D cells after 72 hrs by MTT assay, IC50 = 6.08 μM. |
23521020 |
A549 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay, IC50 = 6.63 μM. |
23521020 |
MCF7 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay, IC50 = 6.92 μM. |
23521020 |
BJ |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against human BJ cells after 72 hrs by PrestoBlue colorimetric assay, IC50 = 12.8 μM. |
24835982 |
NCI-H460 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay, IC50 = 14.41 μM. |
23521020 |
BA/F3 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CCK-8 assay, IC50 = 15.1 μM. |
23301703 |
BA/F3 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL T315I mutant assessed as growth inhibition after 72 hrs by CCK-8 assay, IC50 = 16 μM. |
23301703 |
BA/F3 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL H396R mutant assessed as growth inhibition after 72 hrs by CCK-8 assay, IC50 = 21.1 μM. |
23301703 |
BA/F3 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against mouse BA/F3 cells after 72 hrs by CCK-8 assay, IC50 = 40.75 μM. |
23088644 |
HCC2218 |
Growth Inhibition Assay |
|
|
IC50=13.5856 μM |
SANGER |
MN-60 |
Growth Inhibition Assay |
|
|
IC50=13.5843 μM |
SANGER |
A427 |
Growth Inhibition Assay |
|
|
IC50=13.4972 μM |
SANGER |
A4-Fuk |
Growth Inhibition Assay |
|
|
IC50=13.4102 μM |
SANGER |
DB |
Growth Inhibition Assay |
|
|
IC50=13.3256 μM |
SANGER |
ES5 |
Growth Inhibition Assay |
|
|
IC50=13.0512 μM |
SANGER |
AGS |
Growth Inhibition Assay |
|
|
IC50=13.0351 μM |
SANGER |
EW-3 |
Growth Inhibition Assay |
|
|
IC50=12.9307 μM |
SANGER |
NCI-H720 |
Growth Inhibition Assay |
|
|
IC50=12.6801 μM |
SANGER |
HLE |
Growth Inhibition Assay |
|
|
IC50=11.8839 μM |
SANGER |
DSH1 |
Growth Inhibition Assay |
|
|
IC50=11.7953 μM |
SANGER |
NCI-N87 |
Growth Inhibition Assay |
|
|
IC50=11.7731 μM |
SANGER |
697 |
Growth Inhibition Assay |
|
|
IC50=11.2101 μM |
SANGER |
KARPAS-45 |
Growth Inhibition Assay |
|
|
IC50=11.0635 μM |
SANGER |
A2058 |
Growth Inhibition Assay |
|
|
IC50=10.9245 μM |
SANGER |
A101D |
Growth Inhibition Assay |
|
|
IC50=10.8923 μM |
SANGER |
HL-60 |
Growth Inhibition Assay |
|
|
IC50=10.6853 μM |
SANGER |
HEC-1 |
Growth Inhibition Assay |
|
|
IC50=10.2804 μM |
SANGER |
MLMA |
Growth Inhibition Assay |
|
|
IC50=10.0132 μM |
SANGER |
LB771-HNC |
Growth Inhibition Assay |
|
|
IC50=9.76497 μM |
SANGER |
KYSE-520 |
Growth Inhibition Assay |
|
|
IC50=9.33482 μM |
SANGER |
ACHN |
Growth Inhibition Assay |
|
|
IC50=9.23632 μM |
SANGER |
GCT |
Growth Inhibition Assay |
|
|
IC50=9.09831 μM |
SANGER |
BCPAP |
Growth Inhibition Assay |
|
|
IC50=9.02562 μM |
SANGER |
CTB-1 |
Growth Inhibition Assay |
|
|
IC50=8.87128 μM |
SANGER |
D-423MG |
Growth Inhibition Assay |
|
|
IC50=8.83756 μM |
SANGER |
MOLT-4 |
Growth Inhibition Assay |
|
|
IC50=8.62353 μM |
SANGER |
COLO-668 |
Growth Inhibition Assay |
|
|
IC50=8.59491 μM |
SANGER |
NUGC-3 |
Growth Inhibition Assay |
|
|
IC50=8.53582 μM |
SANGER |
UM-UC-3 |
Growth Inhibition Assay |
|
|
IC50=8.43956 μM |
SANGER |
A388 |
Growth Inhibition Assay |
|
|
IC50=8.38481 μM |
SANGER |
EW-13 |
Growth Inhibition Assay |
|
|
IC50=8.32054 μM |
SANGER |
COLO-679 |
Growth Inhibition Assay |
|
|
IC50=7.98671 μM |
SANGER |
SK-MEL-24 |
Growth Inhibition Assay |
|
|
IC50=7.63392 μM |
SANGER |
D-566MG |
Growth Inhibition Assay |
|
|
IC50=7.47155 μM |
SANGER |
HDLM-2 |
Growth Inhibition Assay |
|
|
IC50=7.40149 μM |
SANGER |
RPMI-8226 |
Growth Inhibition Assay |
|
|
IC50=7.28287 μM |
SANGER |
MS-1 |
Growth Inhibition Assay |
|
|
IC50=7.11953 μM |
SANGER |
HuO9 |
Growth Inhibition Assay |
|
|
IC50=6.73964 μM |
SANGER |
Ramos-2G6-4C10 |
Growth Inhibition Assay |
|
|
IC50=6.66931 μM |
SANGER |
NY |
Growth Inhibition Assay |
|
|
IC50=6.53599 μM |
SANGER |
IGROV-1 |
Growth Inhibition Assay |
|
|
IC50=6.47191 μM |
SANGER |
MDA-MB-361 |
Growth Inhibition Assay |
|
|
IC50=6.33699 μM |
SANGER |
CAL-33 |
Growth Inhibition Assay |
|
|
IC50=6.31359 μM |
SANGER |
K-562 |
Growth Inhibition Assay |
|
|
IC50=5.9036 μM |
SANGER |
RVH-421 |
Growth Inhibition Assay |
|
|
IC50=5.77536 μM |
SANGER |
LCLC-103H |
Growth Inhibition Assay |
|
|
IC50=5.77471 μM |
SANGER |
CTV-1 |
Growth Inhibition Assay |
|
|
IC50=5.48938 μM |
SANGER |
SBC-1 |
Growth Inhibition Assay |
|
|
IC50=4.90907 μM |
SANGER |
HAL-01 |
Growth Inhibition Assay |
|
|
IC50=4.88242 μM |
SANGER |
SK-NEP-1 |
Growth Inhibition Assay |
|
|
IC50=4.83191 μM |
SANGER |
HOS |
Growth Inhibition Assay |
|
|
IC50=4.80282 μM |
SANGER |
G-402 |
Growth Inhibition Assay |
|
|
IC50=4.31203 μM |
SANGER |
HT-1080 |
Growth Inhibition Assay |
|
|
IC50=3.91775 μM |
SANGER |
SW982 |
Growth Inhibition Assay |
|
|
IC50=3.64169 μM |
SANGER |
L-363 |
Growth Inhibition Assay |
|
|
IC50=3.61107 μM |
SANGER |
SK-MEL-1 |
Growth Inhibition Assay |
|
|
IC50=3.43029 μM |
SANGER |
NCI-SNU-1 |
Growth Inhibition Assay |
|
|
IC50=3.40092 μM |
SANGER |
T98G |
Growth Inhibition Assay |
|
|
IC50=3.01313 μM |
SANGER |
JAR |
Growth Inhibition Assay |
|
|
IC50=2.92084 μM |
SANGER |
RS4-11 |
Growth Inhibition Assay |
|
|
IC50=2.90623 μM |
SANGER |
NOS-1 |
Growth Inhibition Assay |
|
|
IC50=2.87102 μM |
SANGER |
HCC1806 |
Growth Inhibition Assay |
|
|
IC50=2.74327 μM |
SANGER |
H9 |
Growth Inhibition Assay |
|
|
IC50=2.73793 μM |
SANGER |
HOP-62 |
Growth Inhibition Assay |
|
|
IC50=1.82077 μM |
SANGER |
A204 |
Growth Inhibition Assay |
|
|
IC50=1.57205 μM |
SANGER |
ACN |
Growth Inhibition Assay |
|
|
IC50=1.55077 μM |
SANGER |
BE-13 |
Growth Inhibition Assay |
|
|
IC50=1.27416 μM |
SANGER |
NCI-H1703 |
Growth Inhibition Assay |
|
|
IC50=1.1887 μM |
SANGER |
LB2241-RCC |
Growth Inhibition Assay |
|
|
IC50=1.02228 μM |
SANGER |
NKM-1 |
Growth Inhibition Assay |
|
|
IC50=0.9015 μM |
SANGER |
HMV-II |
Growth Inhibition Assay |
|
|
IC50=0.74874 μM |
SANGER |
CGTH-W-1 |
Growth Inhibition Assay |
|
|
IC50=0.6487 μM |
SANGER |
BHT-101 |
Growth Inhibition Assay |
|
|
IC50=0.64263 μM |
SANGER |
NB7 |
Growth Inhibition Assay |
|
|
IC50=0.13439 μM |
SANGER |
KASUMI-1 |
Growth Inhibition Assay |
|
|
IC50=0.02413 μM |
SANGER |
BV-173 |
Growth Inhibition Assay |
|
|
IC50=0.01089 μM |
SANGER |
MEG-01 |
Growth Inhibition Assay |
|
|
IC50=0.00828 μM |
SANGER |
LAMA-84 |
Growth Inhibition Assay |
|
|
IC50=0.0049 μM |
SANGER |
EM-2 |
Growth Inhibition Assay |
|
|
IC50=0.0041 μM |
SANGER |
KU812 |
Growth Inhibition Assay |
|
|
IC50=0.00248 μM |
SANGER |
EoL-1-cell |
Growth Inhibition Assay |
|
|
IC50=0.000144 μM |
SANGER |
MV-4-11 |
Growth Inhibition Assay |
|
|
IC50=13.8137 μM |
SANGER |
GI-1 |
Growth Inhibition Assay |
|
|
IC50=14.1184 μM |
SANGER |
JVM-3 |
Growth Inhibition Assay |
|
|
IC50=14.2656 μM |
SANGER |
NCI-H2029 |
Growth Inhibition Assay |
|
|
IC50=14.2727 μM |
SANGER |
TE-12 |
Growth Inhibition Assay |
|
|
IC50=14.6046 μM |
SANGER |
WM-115 |
Growth Inhibition Assay |
|
|
IC50=15.5683 μM |
SANGER |
BB65-RCC |
Growth Inhibition Assay |
|
|
IC50=16.0241 μM |
SANGER |
NCI-H1693 |
Growth Inhibition Assay |
|
|
IC50=16.3802 μM |
SANGER |
KARPAS-299 |
Growth Inhibition Assay |
|
|
IC50=16.6203 μM |
SANGER |
UACC-257 |
Growth Inhibition Assay |
|
|
IC50=17.0582 μM |
SANGER |
RKO |
Growth Inhibition Assay |
|
|
IC50=17.6433 μM |
SANGER |
HT-29 |
Growth Inhibition Assay |
|
|
IC50=17.7889 μM |
SANGER |
ES7 |
Growth Inhibition Assay |
|
|
IC50=18.1122 μM |
SANGER |
DEL |
Growth Inhibition Assay |
|
|
IC50=18.3172 μM |
SANGER |
BT-549 |
Growth Inhibition Assay |
|
|
IC50=18.4092 μM |
SANGER |
NCI-H1755 |
Growth Inhibition Assay |
|
|
IC50=18.5723 μM |
SANGER |
HCE-T |
Growth Inhibition Assay |
|
|
IC50=18.8341 μM |
SANGER |
LU-139 |
Growth Inhibition Assay |
|
|
IC50=19.0458 μM |
SANGER |
ECC10 |
Growth Inhibition Assay |
|
|
IC50=19.2475 μM |
SANGER |
769-P |
Growth Inhibition Assay |
|
|
IC50=19.6335 μM |
SANGER |
BALL-1 |
Growth Inhibition Assay |
|
|
IC50=19.6775 μM |
SANGER |
LXF-289 |
Growth Inhibition Assay |
|
|
IC50=19.8979 μM |
SANGER |
TYK-nu |
Growth Inhibition Assay |
|
|
IC50=19.9315 μM |
SANGER |
NCI-H630 |
Growth Inhibition Assay |
|
|
IC50=19.9378 μM |
SANGER |
EW-18 |
Growth Inhibition Assay |
|
|
IC50=20.3802 μM |
SANGER |
KYSE-150 |
Growth Inhibition Assay |
|
|
IC50=20.7047 μM |
SANGER |
LOXIMVI |
Growth Inhibition Assay |
|
|
IC50=20.7586 μM |
SANGER |
HuP-T3 |
Growth Inhibition Assay |
|
|
IC50=21.0852 μM |
SANGER |
MFE-280 |
Growth Inhibition Assay |
|
|
IC50=21.5679 μM |
SANGER |
SK-OV-3 |
Growth Inhibition Assay |
|
|
IC50=21.8408 μM |
SANGER |
QIMR-WIL |
Growth Inhibition Assay |
|
|
IC50=22.0478 μM |
SANGER |
NCI-H69 |
Growth Inhibition Assay |
|
|
IC50=22.4299 μM |
SANGER |
TE-5 |
Growth Inhibition Assay |
|
|
IC50=22.4965 μM |
SANGER |
NCI-H1993 |
Growth Inhibition Assay |
|
|
IC50=22.4971 μM |
SANGER |
NCI-H1092 |
Growth Inhibition Assay |
|
|
IC50=23.2843 μM |
SANGER |
RH-1 |
Growth Inhibition Assay |
|
|
IC50=23.5357 μM |
SANGER |
DBTRG-05MG |
Growth Inhibition Assay |
|
|
IC50=23.8472 μM |
SANGER |
Mo-T |
Growth Inhibition Assay |
|
|
IC50=23.9 μM |
SANGER |
HD-MY-Z |
Growth Inhibition Assay |
|
|
IC50=24.2362 μM |
SANGER |
NCI-H2342 |
Growth Inhibition Assay |
|
|
IC50=24.6767 μM |
SANGER |
C32 |
Growth Inhibition Assay |
|
|
IC50=24.9576 μM |
SANGER |
HTC-C3 |
Growth Inhibition Assay |
|
|
IC50=25.3577 μM |
SANGER |
NCI-H358 |
Growth Inhibition Assay |
|
|
IC50=25.3943 μM |
SANGER |
CAL-85-1 |
Growth Inhibition Assay |
|
|
IC50=25.4577 μM |
SANGER |
HT-1197 |
Growth Inhibition Assay |
|
|
IC50=25.5319 μM |
SANGER |
A172 |
Growth Inhibition Assay |
|
|
IC50=25.7136 μM |
SANGER |
SW1573 |
Growth Inhibition Assay |
|
|
IC50=25.7785 μM |
SANGER |
EW-24 |
Growth Inhibition Assay |
|
|
IC50=25.962 μM |
SANGER |
SK-MEL-2 |
Growth Inhibition Assay |
|
|
IC50=26.0312 μM |
SANGER |
LU-65 |
Growth Inhibition Assay |
|
|
IC50=26.0452 μM |
SANGER |
KMOE-2 |
Growth Inhibition Assay |
|
|
IC50=26.0915 μM |
SANGER |
H-EMC-SS |
Growth Inhibition Assay |
|
|
IC50=26.4114 μM |
SANGER |
H4 |
Growth Inhibition Assay |
|
|
IC50=26.4243 μM |
SANGER |
DU-4475 |
Growth Inhibition Assay |
|
|
IC50=27.1872 μM |
SANGER |
HCT-116 |
Growth Inhibition Assay |
|
|
IC50=27.4349 μM |
SANGER |
MSTO-211H |
Growth Inhibition Assay |
|
|
IC50=27.6255 μM |
SANGER |
NCI-H292 |
Growth Inhibition Assay |
|
|
IC50=27.9617 μM |
SANGER |
NCI-H446 |
Growth Inhibition Assay |
|
|
IC50=28.2105 μM |
SANGER |
NCI-H2009 |
Growth Inhibition Assay |
|
|
IC50=29.1431 μM |
SANGER |
MHH-ES-1 |
Growth Inhibition Assay |
|
|
IC50=29.3685 μM |
SANGER |
TI-73 |
Growth Inhibition Assay |
|
|
IC50=29.4001 μM |
SANGER |
NCI-H2228 |
Growth Inhibition Assay |
|
|
IC50=29.458 μM |
SANGER |
MHH-PREB-1 |
Growth Inhibition Assay |
|
|
IC50=29.5505 μM |
SANGER |
ChaGo-K-1 |
Growth Inhibition Assay |
|
|
IC50=29.6097 μM |
SANGER |
KY821 |
Growth Inhibition Assay |
|
|
IC50=29.6433 μM |
SANGER |
NCI-H209 |
Growth Inhibition Assay |
|
|
IC50=29.8366 μM |
SANGER |
NBsusSR |
Growth Inhibition Assay |
|
|
IC50=29.9904 μM |
SANGER |
NCI-H1304 |
Growth Inhibition Assay |
|
|
IC50=30.5716 μM |
SANGER |
NB14 |
Growth Inhibition Assay |
|
|
IC50=31.0446 μM |
SANGER |
HCC1419 |
Growth Inhibition Assay |
|
|
IC50=31.24 μM |
SANGER |
KG-1 |
Growth Inhibition Assay |
|
|
IC50=31.7429 μM |
SANGER |
A2780 |
Growth Inhibition Assay |
|
|
IC50=31.8358 μM |
SANGER |
NCI-H28 |
Growth Inhibition Assay |
|
|
IC50=31.9861 μM |
SANGER |
C2BBe1 |
Growth Inhibition Assay |
|
|
IC50=32.2634 μM |
SANGER |
VA-ES-BJ |
Growth Inhibition Assay |
|
|
IC50=32.31 μM |
SANGER |
SBC-5 |
Growth Inhibition Assay |
|
|
IC50=32.8511 μM |
SANGER |
OVCAR-4 |
Growth Inhibition Assay |
|
|
IC50=33.4848 μM |
SANGER |
COR-L88 |
Growth Inhibition Assay |
|
|
IC50=34.0741 μM |
SANGER |
SW954 |
Growth Inhibition Assay |
|
|
IC50=34.0752 μM |
SANGER |
COLO-684 |
Growth Inhibition Assay |
|
|
IC50=34.3404 μM |
SANGER |
HCC70 |
Growth Inhibition Assay |
|
|
IC50=34.9514 μM |
SANGER |
NCI-H1770 |
Growth Inhibition Assay |
|
|
IC50=34.961 μM |
SANGER |
NCI-H1666 |
Growth Inhibition Assay |
|
|
IC50=35.8253 μM |
SANGER |
YH-13 |
Growth Inhibition Assay |
|
|
IC50=35.92 μM |
SANGER |
DJM-1 |
Growth Inhibition Assay |
|
|
IC50=36.8049 μM |
SANGER |
KNS-62 |
Growth Inhibition Assay |
|
|
IC50=36.9438 μM |
SANGER |
SK-MEL-30 |
Growth Inhibition Assay |
|
|
IC50=37.8737 μM |
SANGER |
SJRH30 |
Growth Inhibition Assay |
|
|
IC50=38.7341 μM |
SANGER |
GP5d |
Growth Inhibition Assay |
|
|
IC50=38.8653 μM |
SANGER |
SW1116 |
Growth Inhibition Assay |
|
|
IC50=39.2805 μM |
SANGER |
COLO-800 |
Growth Inhibition Assay |
|
|
IC50=39.3638 μM |
SANGER |
RD |
Growth Inhibition Assay |
|
|
IC50=39.5258 μM |
SANGER |
NCI-SNU-5 |
Growth Inhibition Assay |
|
|
IC50=39.6916 μM |
SANGER |
HuO-3N1 |
Growth Inhibition Assay |
|
|
IC50=40.108 μM |
SANGER |
SK-UT-1 |
Growth Inhibition Assay |
|
|
IC50=40.5674 μM |
SANGER |
SK-MEL-3 |
Growth Inhibition Assay |
|
|
IC50=40.5932 μM |
SANGER |
SK-MEL-28 |
Growth Inhibition Assay |
|
|
IC50=40.6435 μM |
SANGER |
SCC-4 |
Growth Inhibition Assay |
|
|
IC50=41.2137 μM |
SANGER |
no-11 |
Growth Inhibition Assay |
|
|
IC50=41.7354 μM |
SANGER |
HT-144 |
Growth Inhibition Assay |
|
|
IC50=42.0567 μM |
SANGER |
MFM-223 |
Growth Inhibition Assay |
|
|
IC50=42.402 μM |
SANGER |
ONS-76 |
Growth Inhibition Assay |
|
|
IC50=42.8018 μM |
SANGER |
ES8 |
Growth Inhibition Assay |
|
|
IC50=43.3698 μM |
SANGER |
T-24 |
Growth Inhibition Assay |
|
|
IC50=43.4369 μM |
SANGER |
GAMG |
Growth Inhibition Assay |
|
|
IC50=43.4517 μM |
SANGER |
LU-135 |
Growth Inhibition Assay |
|
|
IC50=44.0923 μM |
SANGER |
HCC1187 |
Growth Inhibition Assay |
|
|
IC50=44.8262 μM |
SANGER |
TE-1 |
Growth Inhibition Assay |
|
|
IC50=45.1654 μM |
SANGER |
J-RT3-T3-5 |
Growth Inhibition Assay |
|
|
IC50=45.4315 μM |
SANGER |
GI-ME-N |
Growth Inhibition Assay |
|
|
IC50=45.8952 μM |
SANGER |
D-392MG |
Growth Inhibition Assay |
|
|
IC50=45.9256 μM |
SANGER |
KALS-1 |
Growth Inhibition Assay |
|
|
IC50=46.7257 μM |
SANGER |
MMAC-SF |
Growth Inhibition Assay |
|
|
IC50=46.9952 μM |
SANGER |
HSC-3 |
Growth Inhibition Assay |
|
|
IC50=47.3608 μM |
SANGER |
KM-H2 |
Growth Inhibition Assay |
|
|
IC50=47.6007 μM |
SANGER |
LoVo |
Growth Inhibition Assay |
|
|
IC50=48.1002 μM |
SANGER |
NCI-H510A |
Growth Inhibition Assay |
|
|
IC50=48.1871 μM |
SANGER |
EW-11 |
Growth Inhibition Assay |
|
|
IC50=48.2348 μM |
SANGER |
HCC2998 |
Growth Inhibition Assay |
|
|
IC50=48.6236 μM |
SANGER |
J82 |
Growth Inhibition Assay |
|
|
IC50=48.7242 μM |
SANGER |
ML-2 |
Growth Inhibition Assay |
|
|
IC50=49.4605 μM |
SANGER |
NCI-H2030 |
Growth Inhibition Assay |
|
|
IC50=49.7117 μM |
SANGER |
NCI-H1792 |
Growth Inhibition Assay |
|
|
IC50=49.8518 μM |
SANGER |
KU812 |
Antiproliferative assay |
|
|
Antiproliferative activity against human KU812 cells, IC50 = 0.0034 μM. |
21376587 |
HEK293 |
Function assay |
|
|
Inhibition of autophosphorylation of DDR1 expressed in HEK293 cells by ELISA, IC50 = 0.0037 μM. |
20817538 |
HEK293 |
Function assay |
|
|
Inhibition of autophosphorylation of DDR2 expressed in HEK293 cells by ELISA, IC50 = 0.0052 μM. |
20817538 |
K562 |
Antiproliferative assay |
|
|
Antiproliferative activity against human K562 cells, IC50 = 0.0065 μM. |
21376587 |
Ba/F |
Function assay |
|
|
Inhibition of autophosphorylation of BCR-ABL1 expressed in Ba/F cells, IC50 = 0.02 μM. |
20817538 |
K562 |
Antiproliferative assay |
|
|
Antiproliferative activity against human K562 cells, IC50 = 0.021 μM. |
20817538 |
BA/F3 |
Antiproliferative assay |
|
|
Antiproliferative activity against BCR-ABL1 transfected mouse BA/F3 cells, IC50 = 0.025 μM. |
20817538 |
K562 |
Function assay |
|
|
Inhibition of BCR-ABL1 autophosphorylation in human K562 cells, IC50 = 0.042 μM. |
20817538 |
BA/F3 |
Antiproliferative assay |
|
|
Antiproliferative activity against PDGFRbeta transfected mouse BA/F3 cells, IC50 = 0.062 μM. |
20817538 |
A31 |
Function assay |
|
|
Inhibition of human PDGFRalpha autophosphorylation in human A31 cells by ELISA, IC50 = 0.071 μM. |
20817538 |
A31 |
Function assay |
|
|
Inhibition of PDGFRbeta autophosphorylation in human A31 cells by ELISA, IC50 = 0.071 μM. |
20817538 |
GIST882 |
Antiproliferative assay |
|
|
Antiproliferative activity against human GIST882 cells, IC50 = 0.151 μM. |
20817538 |
GIST882 |
Function assay |
|
|
Inhibition of human KIT autophosphorylation in human GIST882 cells by ELISA, IC50 = 0.217 μM. |
20817538 |
K562 |
Antiproliferative assay |
|
|
Antiproliferative activity against human imatinib-resistant K562 cells, IC50 = 0.26 μM. |
21376587 |
HEK293 |
Function assay |
|
|
Inhibition of autophosphorylation of CSF1R expressed in HEK293 cells by ELISA, IC50 = 0.677 μM. |
20817538 |
M-NFS-60 |
Antiproliferative assay |
|
|
Antiproliferative activity against mouse M-NFS-60 cells, IC50 = 0.838 μM. |
20817538 |
CHO |
Function assay |
|
|
Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits, IC50 = 4.7 μM. |
23812503 |
SJ-GBM2 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells |
29435139 |
NB-EBc1 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells |
29435139 |
NB1643 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells |
29435139 |
A673 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) |
29435139 |
LAN-5 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells |
29435139 |
BT-37 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells |
29435139 |
Rh41 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells |
29435139 |
Rh30 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells |
29435139 |
OHS-50 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells |
29435139 |
SK-N-SH |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells |
29435139 |